| Literature DB >> 33261292 |
C Perisano1,2, R Vitiello1,2, A Sgambato1,2, T Greco1,2, L Cianni1,2, G Ragonesi2, T Malara3, G Maccauro1,2, M Martini1.
Abstract
Sarcomas are a heterogeneous group of rare tumours. Improvements in immunotherapy and the important role of PD1 and PD-L1 expression in advancement and prognosis have opened new fields of research for the treatment of these neoplasia. We evaluated the immunohistochemistry of PD1 and PD-L1 expression in 60 adults' patients affected by high-grade sarcomas of the limbs. PD1 expression was 65% while PD-L1 was 68.3%. PD-L1 expression seems to correlate to Ki67 in liposarcomas, fibrosarcoma's and pleomorphic sarcomas, while it does not show any correlation to chondrosarcomas, while in rhabdomyosarcomas there is a correlation but, given the small sample size, it was not possible to perform a statistic analysis. Our study shows positivity among the different subgroups of positive PD1 lymphocytes infiltration and PD-L1 expression in high-grade sarcomas of the limbs. Copyright 2020 Biolife Sas. www.biolifesas.org.Entities:
Keywords: PD; PD-L1; immunotherapy; programmed cell death receptor; sarcoma
Year: 2020 PMID: 33261292
Source DB: PubMed Journal: J Biol Regul Homeost Agents ISSN: 0393-974X Impact factor: 1.711